A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre
A phase 1/2 trial of Mezigdomide, Bortezomib, Dexamethasone in multiple myeloma, run by Celgene, active and no longer recruiting.
Overview
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) is a phase 1/2 interventional study registered as NCT03989414 by Celgene, with 424 participants planned, started 2019-09-30 and due to reach its primary completion in 2026-11-30. Interventions recorded: CC-92480, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W
Shares Mezigdomide, Carfilzomib, Dexamethasone, Bristol Myers Squibb.
- TrialA Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple
Shares Carfilzomib, Bortezomib, Daratumumab, Dexamethasone.
- TrialA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re
Shares Mezigdomide, Bortezomib, Dexamethasone, Bristol Myers Squibb.
- TrialMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other
Shares Elotuzumab, Carfilzomib, Bortezomib, Dexamethasone.
- TrialStudy Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto
Shares Elotuzumab, Carfilzomib, Bortezomib, Dexamethasone.
- TrialA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe
Shares Mezigdomide, Carfilzomib, Daratumumab, Dexamethasone.
- TrialOpen-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants
Shares Bortezomib, Daratumumab, Dexamethasone, Bristol Myers Squibb.
- TrialA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela
Shares Carfilzomib, Bortezomib, Daratumumab, Dexamethasone.